Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has maintained a Speculative Buy rating on Genelux Corporation (NASDAQ:GNLX) but has reduced the price target from $38 to $30.
November 24, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Benchmark analyst Bruce Jackson maintains a Speculative Buy on Genelux but lowers the price target from $38 to $30, indicating a potential downside compared to the previous target.
The reduction in price target by Benchmark analyst Bruce Jackson for Genelux suggests a tempered expectation for the stock's future price performance, which could lead to a negative short-term impact on the stock price. Investors may view the lower price target as a sign of reduced growth prospects or potential challenges ahead for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100